Mixed results for REGN-3500’s phase II asthma trial dent IL-33 rival Anaptysbio

0
84

Top-line data for Sanofi SA and Regeneron Pharmaceuticals Inc.’s phase II trial of the IL-33 antibody REGN-3500 show patients with moderate to severe asthma treated with Dupixent (dupilumab) monotherapy did numerically better than REGN-3500 across all endpoints. And combining REGN-3500 and Dupixent did not demonstrate increased benefit compared to Dupixent monotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here